Provided by Tiger Trade Technology Pte. Ltd.

ANI Pharmaceuticals

72.82
-1.3200-1.78%
Post-market: 72.820.00000.00%16:59 EDT
Volume:130.72K
Turnover:9.56M
Market Cap:1.64B
PE:21.91
High:74.65
Open:73.95
Low:72.60
Close:74.14
52wk High:99.50
52wk Low:56.71
Shares:22.47M
Float Shares:20.38M
Volume Ratio:0.47
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.32
EPS(LYR):3.32
ROE:16.16%
ROA:3.82%
PB:3.03
PE(LYR):21.93

Loading ...

ANI Pharmaceuticals Outlook FY Revenue USD 1,055-1,115 Million

THOMSON REUTERS
·
Feb 27

ANI Pharmaceuticals Outlook FY Adjusted EPS USD 8.83-9.34

THOMSON REUTERS
·
Feb 27

ANI Pharmaceuticals Inc FY2026 Shr View $8.58, REV View $982.5 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
Feb 27

ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance

THOMSON REUTERS
·
Feb 27

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 27

ANI Pharmaceuticals to Present at Upcoming Investor Conferences

Reuters
·
Feb 24

ANI Pharmaceuticals Head of Rare Disease Christopher Mutz Disposes of Common Shares

Reuters
·
Feb 24

Earning Preview: ANI Pharmaceuticals this quarter’s revenue is expected to increase by 32.03%, and institutional views are predominantly bullish

Earnings Agent
·
Feb 20

Christopher Mutz, Head of Rare Disease, reports disposal of ANI Pharmaceuticals Inc. common shares

Reuters
·
Feb 18

ANI Pharmaceuticals SVP Meredith Cook Reports Disposal of Common Shares

Reuters
·
Feb 18

ANI Pharmaceuticals Inc. to Announce Fourth Quarter and Full Year Financial Results

Reuters
·
Feb 13

ANI Pharmaceuticals (ANIP) Is Up 11.2% After Raising 2026 Revenue Outlook And Rare Disease Hiring Plan – Has The Bull Case Changed?

Simply Wall St.
·
Jan 17

ANI Pharmaceuticals Is Maintained at Buy by Guggenheim

Dow Jones
·
Jan 16

ANI Pharmaceuticals Sr. VP Meredith Cook Reports Sale of Common Shares

Reuters
·
Jan 15

Guggenheim Reaffirms Their Buy Rating on ANI Pharmaceuticals (ANIP)

TIPRANKS
·
Jan 13

ANI Pharmaceuticals issues strong 2025 preliminary results, 2026 outlook

TIPRANKS
·
Jan 13

ANI Pharmaceuticals Shares up 10.6% Premarket After Forecasting FY26 Revenue Above Estimates

THOMSON REUTERS
·
Jan 12

GUIDANCE: (ANIP) ANI Pharmaceuticals Expects 2026 Revenue Range $1.06B - $1.12B, vs. FactSet Est of $955.1M

MT Newswires Live
·
Jan 12

BRIEF-ANI Pharmaceuticals Q4 Revenue USD 111.4 Million Vs. IBES Estimate USD 225.2 Million

Reuters
·
Jan 12

ANI Pharmaceuticals Projects Up to $1.115 Billion in 2026 Revenue

Reuters
·
Jan 12